Jump to content

25I-NB4OMe

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ffffrr (talk | contribs) at 02:30, 26 April 2022 (Importing Wikidata short description: "Chemical compound" (Shortdesc helper)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

25I-NB4OMe
Clinical data
ATC code
  • none
Identifiers
  • 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H22INO3
Molar mass427.282 g·mol−1
3D model (JSmol)
  • COC1=CC=C(C=C1)CNCCC2=CC(=C(C=C2OC)I)OC
  • InChI=NWOROGLTELSWAZ-UHFFFAOYSA-N
  • Key:NWOROGLTELSWAZ-UHFFFAOYSA-N

25I-NB4OMe (2C-I-NB4OMe, NB4OMe-2C-I) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1]

Legality

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[2]

References

  1. ^ https://bitnest.netfirms.com/external.php?id=%2501%253B5%25168%250F%2518%250DG%257F%255B18%2521UYHRO%2500JAsca%2515%255C[permanent dead link]
  2. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.